Age, Genetics Modify PD Risk With Pesticides

BY JEFF EVANS

The risk for developing Parkinson’s disease that is associated with pesticide exposure appears to be especially high in people who are professionally exposed to the chemicals and those who carry certain polymorphisms for glutathione S-transferase genes, according to findings from two new case-control studies.

The studies strengthen the already well-documented association between pesticide exposure and Parkinson’s disease (PD) by including a more detailed assessment of exposure to the chemicals for analyzing dose-effect relationships, especially for different classes of insecticides, fungicides, and herbicides, as well as examining the role of genetic traits in determining individual susceptibility to PD.

Dr. Alex Elbaz of the Institut National de la Santé et de la Recherche Médicale, Paris, and his colleagues conducted extensive in-person interviews about professional exposure to pesticides with 247 patients with PD and 676 matching control patients. All of the participants came from the same French health insurance organization for workers in agriculture and related occupations. The patients with PD had been diagnosed a median of 3.5 years before the study (Ann. Neurol. 2009;66:1002–1017).

Dr. Elbaz and his associates found that for men, the odds of developing PD increased with the number of years of professional use of pesticides. This relationship was stronger for men with PD onset after age 65 years than it was for men with younger onset. Women with pesticide exposure also were significantly more likely to develop PD than those without exposure.

Only insecticide exposure in men was associated with a significantly increased odds of developing PD (odds ratio 2.2). This association followed a dose-effect relationship, which was strongest for older-onset PD patients. In women, only fungicide exposure was associated with significantly increased odds of developing PD (odds ratio 3.5).

In multivariate analyses of men overall and of men with older-onset PD, only organochlorine insecticides remained associated with PD after adjusting for other pesticide families that the men had been exposed to.

The finding that the association between PD and professional pesticide use was stronger for older males is “consistent with the view that genetic susceptibility plays a stronger role in younger-onset cases, while environmental factors play a stronger role for older-onset cases,” the investigators wrote.

This was supported in the study by a similar number of years of pesticide exposure between both older-onset cases (13 years) and in younger-onset cases (12 years) and a higher cumulative lifetime hours of exposure for younger-onset cases (88 hours), compared with older-onset cases (52 hours).

In a separate study, Dr. Ruey-Meei Wu of the department of neurology at National Taiwan University Hospital, Taipei, and her coinvestigators genotyped 125 patients (69 women) with sporadic idiopathic PD and 162 age- and gender-matched control patients (90 women) from a rural area of southern Taiwan for four glutathione S-transferase (GST) genes (GSTM1, GSTP1, GSTT1, and GSTZ1).

Overall, 69 PD patients and 70 control patients were exposed to pesticides used in professional farming or gardening. These patients had been exposed to pesticides for a range of 1 to 50 years, Dr. Wu and her colleagues reported at a poster session of the International Congress of Parkinson’s Disease and Movement Disorders.

The risk of Parkinson’s disease with professional pesticide exposure may increase with genetic susceptibility and older age.

 orders in Paris.

GST polymorphisms have been reported to reduce the efficiency of the substrate selectivity or stability of the enzymes. In brain tissue, GSTs function as scavengers that eliminate the formation of intracellular free radicals that are generated from metabolite activity. GSTs have the potential to modify a person’s susceptibility to developing PD after pesticide exposure by increasing oxidative stress in the brain, leading to the degeneration of dopaminergic neurons, Dr. Wu said in an interview.

Pesticide exposure was an independent risk factor for PD. Only the GSTP1 Val105 polymorphism, which occurred in about 20% of the patients, significantly increased the risk for the development of PD. This polymorphism raised the odds of developing PD by a factor of 2.2. The risk for PD was greatest among patients who had been exposed to pesticides for more than 35 years.

Those who carried the GSTP1 Val105 polymorphism and were exposed to pesticides had even higher risk of developing PD. This was a trend for increasing PD risk that became stronger and more significant in pesticide-exposed patients who carried an additional putative high-risk GST genotype.

None of the investigators in either study had any conflicts of interest to declare.

Pilot Study Shows Feasibility of Telemedicine for Parkinson’s

BY REESE MATTHEWS

Using telemedicine to evaluate patients with Parkinson’s disease is reliable and feasible, according to data from a small, randomized, controlled pilot study of nursing home and community-dwelling patients.

According to the abstract, patients in the study with Parkinson’s disease (PD) who received telematic care over the course of 6 months showed improvements in quality of life, mood, satisfaction with care, cognition, and motor function, compared with those who received standard care, Dr. Kevin M. Biglan and Dr. Ray Dorsey of the University of Rochester (N.Y.) and their colleagues reported at the International Congress of Parkinson’s Disease and Movement Disorders.

Telematic assessments of the motor Unified Parkinson’s Disease Rating Scale (UPDRS) also were reliable and valid, compared with the standard in-person assessment of these patients.

The researchers enrolled 14 patients who lived 150 miles or more from the university (4 in a nursing home and 10 who lived in the community nearby). By providing the patients with Web-based telemedicine, they sought to improve their access to specialized care. They also hoped to show that telemedicine would help expand the pool of Parkinson’s patients who could participate in clinical trials if the logistics and difficulties relating to travel and costs were eliminated.

At baseline, the participants were a mean age of 71 years, and half were women. They had a mean Hoehn & Yahr stage of 2.7 (which ranges from 1 to 5) and a mean motor UPDRS of 34.7 (which is measured from 1 to 108, with a higher score indicating greater disability).

The 10 telemedicine participants were randomized to telemedicine care (6 patients) or standard care (4 patients). All four nursing home patients received telematic care. Participants in the telemedicine group received three one-on-one visits over 6 months (month 1, month 2, and month 3) from one of two investigators who were movement disorder specialists.

There was a fourth visit, at 6.5 months, to allow for the test-retest reliability comparison of the 6- and 6.5-month motor scores.

All of the Web-based teledvelopment assessments were conducted at the nursing home. These assessments mirrored an in-person evaluation, during which participants were asked about their PD, medications, function, and complications of therapy. The investigator performed a motor UPDRS examination at each visit, with a nurse available to assist in performing rigidity testing and pull testing.

Participants in the control group received their standard routine care from their primary physician and/or neurologist.

All of the community-dwelling patients randomized to telemedicine completed all three telemedicine visits. Compared with their standard-care counterparts, they showed significant improvements in quality of life on the EQ-5D (6.3-point improvement vs. 17.2-point deterioration) and the motor UPDRS (0.33 improvement vs. 6.5 deterioration).

The four nursing home participants completed 94% of their telemedicine visits. They showed trends toward improvement in satisfaction with care, quality of life, and depressive symptoms.

All of the motor UPDRS items were able to be completed at each visit, establishing the feasibility of performing the assessment by televideo. All of the motor items were fair or better agreement between telemedicine care after the study was completed.

“...the participation was actually traveling a far distance [for the telemedicine encounter]. Certainly one wonders if providing care in the home or at a closer location would have allowed this individual to continue receiving their care via telemedicine,” Dr. Biglan said in an interview.

In focus group follow-up, both participants and caregivers reported high satisfaction with telemedicine, “especially the decreased travel burden and access to higher quality, dedicated PD experts,” he said.

“They were adamant that telemedicine was convenient and made communicating easy, and despite occasional technological glitches and trouble hearing the doctor, they remained positive.” Nevertheless, “travel remained an issue for some [and] participants had mixed feelings about the possibility of completing telemedicine visits at home without medical and technical support staff.”

The study was funded through the Presbyterian Home for Central New York and the Central New York Parkinson’s Disease Support Group. None of the researchers had any conflicts of interest.